Table 1.

Association between selected immunohistochemical markers and the basal-like phenotype [defined according to Nielsen et al. (6) and Rahka et al. (30) criteria]

VariableNielsen et al. criteriaRakha et al. criteria
Basal groupNonbasal groupχ2 testBasal groupNonbasal groupχ2 test
E-Cadh23/64 (35.9%)198/399 (49.6%)P = 0.04229/83 (34.9%)192/380 (50.5%)P = 0.010
P-Cadh47/62 (75.8%)94/327 (28.7%)P < 0.00156/81 (69.1%)85/308 (27.6%)P < 0.001
N-Cadh10/58 (17.2%)28/325 (8.6%)P = 0.04312/73 (16.4%)26/310 (8.4%)P = 0.038
Cadh-1117/64 (26.6%)47/390 (12.1%)P = 0.00219/83 (23.0%)45/371 (12.1%)P = 0.011
CK 848/67 (71.6%)397/425 (93.4%)P < 0.00169/88 (78.4%)376/404 (93.1%)P < 0.001
CK 1941/67 (61.2%)353/421 (83.8%)P < 0.00157/88 (64.8%)337/400 (84.3%)P < 0.001
CK 5/6 *53/67 (79.1%)24/418 (5.7%)P < 0.00177/88 (87.5%)0/397 (0%)P < 0.001
CK 14 *20/67 (29.9%)13/423 (3.1%)P < 0.00133/88 (37.5%)0/402 (0%)P < 0.001
CD1015/67 (22.4%)33/417 (7.9%)P < 0.00116/87 (18.4%)32/397 (8.1%)P = 0.004
P6314/65 (21.5%)41/420 (9.8%)P = 0.00522/87 (25.3%)33/398 (8.3%)P < 0.001
Laminin35/65 (53.8%)86/417 (20.6%)P < 0.00139/87 (44.8%)82/395 (20.8%)P < 0.001
Fascin29/65 (44.6%)71/418 (17.0%)P < 0.00139/85 (45.9%)61/398 (15.3%)P < 0.001
Vimentin44/67 (65.7%)61/418 (14.6%)P < 0.00148/88 (54.5%)56/399 (14.0%)P < 0.001
SMA14/67 (20.9%)14/420 (3.3%)P < 0.00119/88 (21.6%)9/399 (2.3%)P < 0.001
SPARC20/66 (30.3%)31/411 (7.5%)P < 0.00125/87 (28.7%)26/390 (6.7%)P < 0.001
β-catenin , 10/59 (16.9%)12/392 (3.1%)P < 0.00110/75 (13.3%)12/376 (3.2%)P < 0.001
P120†,‡8/58 (13.8%)22/377 (5.8%)P = 0.0265/72 (6.9%)25/363 (6.9%)NS
Grade I 4/53 (7.5%)55/365 (15.1%)5/68 (7.4%)54/350 (15.2%)
Grade II7/53 (13.2%)157/365 (43.0%)14/68 (20.6%)150/350 (43.0%)
Grade III42/53 (79.2%)153/365 (41.9%)P < 0.00149/68 (72.1%)146/350 (41.8%)P < 0.001
  • Abbreviations: NS, not statistically significant (P > 0.05). Cadh, Cadherin.

  • * Variables included in Nielsen et al. or Rakha et al. criteria to define the basal phenotype.

  • Variables not included in the clustering analysis.

  • Only evaluating cytoplasmic staining.